-
Nucleix Appoints Michael G. Vicari as Chief Commercial Officer Mr. Vicari to plan and lead the company’s commercialization of Lung EpiCheck®
Read MoreSAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced the appointment of commercial
-
Nucleix’s Bladder EpiCheck® Receives FDA 510(k) Clearance for Monitoring of Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence
Read MoreSAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting
-
Nucleix to Premiere Data on its EpiCheck® Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting
Read MoreSAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–
-
Nucleix Receives CAP Accreditation and CLIA Certification for its San Diego Clinical Laboratory
Read MoreSAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting
-
Nucleix Expands EU Label Indication of Bladder EpiCheck® to Include the Detection of Primary Bladder Cancer and Detection of Primary and Recurrent Upper Tract Urinary Cancer
Read MoreSAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting
-
Bladder cancer monitoring can be done via urine test: “More pleasant for the patient and saves time. It also saves hospitals one million euros per year”.
Read MoreBladder cancer monitoring can be done via urine test: “More pleasant for the patient and saves time” “Patients who have had bladder cancer do not always have to go to the hospital
-
The Radboudumc, Nijmegen & Bladder EpiCheck®, won the Silver Award in the “Together in the Lead” Awards from Healthcare Insurer VGZ in the Netherlands.
Read MoreWe are proud to share that the Radboudumc, Nijmegen & Bladder EpiCheck®, won the Silver Award in the “Together in the Lead” Awards from Healthcare Insurer VGZ in the Netherlands. Radboudumc
-
Bladder EpiCheck® Included in 2022 European Association of Urology (EAU) Clinical Guidelines on Non-Muscle Invasive Bladder Cancer (NMIBC) Clinical Guidelines Support Adoption of Urinary Biomarker Tests with High Sensitivity and Negative Predictive Values for High-Grade Disease to Replace and/or Postpone Cystoscopies in Low- and Intermediate-Risk NMIBC Publication of Meta-Analysis in European Urology Oncology Showed Bladder EpiCheck has Best Performance Amongst Guideline-Recommended Urinary Biomarker Tests
Read MoreSAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting
-
Nucleix Announces Recent Advancements in Early Lung Cancer Detection Program
Read MoreSAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “[email protected]”.
Click the confirmation link
Click on the link inside the
email and you’re good to go.